Thiazolidinediones on PPARγ: The Roles in Bone Remodeling | Zendy

Wei Wei | Zendy; Yihong Wan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Thiazolidinediones on PPARγ: The Roles in Bone Remodeling

Author(s) -

Wei Wei,

Yihong Wan

Publication year - 2011

Publication title -

ppar research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.164

H-Index - 49

eISSN - 1687-4765

pISSN - 1687-4757

DOI - 10.1155/2011/867180

Subject(s) - rosiglitazone , bone remodeling , osteoblast , osteoclast , bone resorption , endocrinology , medicine , glucose homeostasis , peroxisome proliferator activated receptor , thiazolidinedione , osteoporosis , receptor , chemistry , diabetes mellitus , type 2 diabetes , insulin resistance , in vitro , biochemistry

Thiazolidinediones (TZDs) are synthetic PPAR γ (peroxisome proliferator-activated receptor gamma) agonists and a class of drugs for diabetes mellitus type 2 that can decrease blood sugar efficiently by enhancing insulin sensitivity. However, increased bone fracture risk in diabetic individuals treated with TZDs is one of the reported side effects. Recent studies show that TZDs such as rosiglitazone simultaneously inhibit osteoblast differentiation and activate osteoclast differentiation, leading to bone loss due to decreased bone formation and increased bone resorption. Furthermore, TZDs may activate PPAR γ in tissues other than bone, such as the hypothalamus-pituitary-gonad (HPG) axis to indirectly regulate bone mass. This paper will focus on current new developments that implicate potential mechanisms for how PPAR γ modulates skeletal homeostasis and how TZDs exert bone-loss side effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research